Novel Presentation of Terminal Ileitis Associated with Secukinumab Therapy.
Case Reports in Gastrointestinal Medicine
Inflammatory bowel disease (IBD) and psoriasis are chronic inflammatory immune-mediated diseases. The interleukin-23- (IL23-) T helper (Th)17 pathway has been implicated in their pathogenesis, with multiple biologic therapies targeting this pathway. IL-17, the main proinflammatory cytokine produced by (TH)17, has been targeted by antibodies and IL-17 receptor blockers with favorable outcomes in treating psoriasis and psoriatic arthritis. However, their role in IBD is unpredictable as studies reported worsening of IBD with agents targeting IL-17 and rare case reports with new-onset IBD. We present a case of Crohn's-like severe terminal ileitis and worsening diverticulitis complicated by intestinal perforation requiring total parenteral nutrition shortly after being started on secukinumab.
Shaheen AA, Hader I, Aqel Z. Novel Presentation of Terminal Ileitis Associated with Secukinumab Therapy. Case Rep Gastrointest Med. 2021 Sep 28;2021:5213876. doi: 10.1155/2021/5213876. PMID: 34621550; PMCID: PMC8492294.